IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. CRCL
6. V
7. GE
8. ASML
9. SPIR
10. NVDA

Go back to IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1149.36 --0 (-0%)
Previous Close $1149.36    52 Week High $88.16 
Open $1149.36    52 Week Low $67.88 
Day High $1149.36    P/E 266.06 
Day Low $1149.36    EPS $4.32 
Volume 28,648